Hansa Biopharma's Major Role at the Upcoming Wedbush PacGrow Renal Summit

Hansa Biopharma AB, a trailblazer in developing immunomodulatory therapies, is preparing for a critical appearance at the Wedbush PacGrow Renal Summit scheduled for July 8, 2026. This event is a notable gathering of key stakeholders in the renal community, and Hansa’s participation is eagerly anticipated.

Maria Törnsén, the Chief Operating Officer and President of Hansa Biopharma in the U.S., is set to take part in a crucial fireside chat entitled "Don't Be So Sensitive - Bringing Kidneys to the Over-Sensitized." This session will be held alongside Dr. Leonardo Riella from Massachusetts General Hospital, and it promises to provide groundbreaking insights into kidney health, particularly pertaining to sensitized patients.

The discussion aims to address the pressing issues faced by highly sensitized kidney transplant patients, focusing on innovative solutions that Hansa has been developing. As sensitization is a significant hurdle in organ transplantation, Hansa’s unique therapies are being highlighted as potential game-changers in this arena.

The Wedbush PacGrow Renal Summit will take place at the Newbury Hotel in Boston, specifically from 1:10 PM to 1:50 PM EDT. This format allows for an intimate and engaging conversation, encouraging active participation from the audience. Hansa's booth will also be available for attendees who wish to delve deeper into their cutting-edge work in immunomodulation and therapeutic options.

Hansa Biopharma, based in Lund, Sweden, is known for its pioneering IgG-cleaving enzyme platform, which targets unmet needs in areas such as transplantation, gene therapy, and autoimmune diseases. Their lead product, imlifidase, has shown potential in enabling kidney transplants for patients with high sensitization levels, showcasing the company's commitment to addressing complex immune disorders. Furthermore, Hansa is advancing the development of projects like HNSA-5487 aimed at Guillain-Barré Syndrome (GBS), indicating the company's broad focus on distinct but related therapeutic areas.

The collaboration of Hansa's leadership team with esteemed medical professionals represents a significant step in advancing the dialogue around renal care. With Hansa's commitment to innovation and enhancing patient outcomes, the discussion led by Törnsén and Riella is expected to shed light on current challenges and possible advancements in kidney transplantation practices.

Attendees of the summit are encouraged to engage with Hansa's representatives during the event. Interested parties can reach out via email to schedule meetings, fostering opportunities for collaboration and information exchange.

In conclusion, Hansa Biopharma’s participation in the Wedbush PacGrow Renal Summit underscores its pivotal role in transforming renal care through innovation. By addressing critical challenges faced by sensitized patients, the company continues to lead the charge towards improved health outcomes in complex medical scenarios. As the date approaches, anticipation builds around the insights and advancements that will emerge from this significant gathering of healthcare leaders and innovators.

For more information about Hansa Biopharma and their initiatives, please visit their official website at Hansa Biopharma.

Event Details:

- Event: Wedbush PacGrow Renal Summit
- Date: July 8, 2026
- Location: Newbury Hotel, Boston
- Time: 1:10 PM - 1:50 PM EDT

Contacts for more information: Kerstin Falck, VP Global Corporate Affairs.

This participation marks another milestone for Hansa Biopharma in its mission to revolutionize treatments for patients facing immune-related challenges.